Health
Baricitinib drug can reduce mortality in patients with moderate to severe COVID-19 – News-Medical.Net
The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research…
Reviewed by Emily Henderson, B.Sc.Nov 16 2020
The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden.
The findings, published in the journal Science Advances, support the continuation of ongoing randomized clinical trials.
“We are pleased to report a 71 percent reduction in mortality for the group…
Continue Reading
